Sarepta Therapeutics Zooms Higher on Early Data Rally Promising
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Identify dividend ETFs with the cheapest expense ratios without sacrificing reliability. This guide helps distinguish leaders in low-cost access.
27,516 articlesSarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
AMD pulled back after a strong rally as investors weigh the impact of the CIQ Linux partnership on AI and data center...
Money moments can feel forced and awkward—whether inflation, debt, or family pressure. This guide turns that discomfo...
Investors who filed their 2025 taxes should act now to optimize retirement income, manage Medicare IRMAA costs, and a...
A fresh partnership announcement sent nano nuclear energy stock higher as investors weigh the promise of small modula...
Trump signals possible U.S. ground action against Mexican cartels, sending ripples through defense stocks and supply ...
This comprehensive analysis breaks down Coinbase's Q1 2026 earnings, explaining revenue mix, margins, and the outlook...
A drone strike lit a cargo ship off Qatar, testing a fragile Iran ceasefire. UAE and Kuwait reported drone incursions...
Credit-card giants are stitching dining platforms, reservations, and rewards into one ecosystem, redefining how consu...
As Uber eyes profitability, a multi-year bull case hinges on margin expansion and stronger bookings. This analysis ou...
A 64-year-old claiming Social Security while working part-time could face a near $13K withholding this year, under th...
As digital money builds pace, the Bank of England signals a nuanced approach to stablecoins. This piece explains what...